Cart
sales@molnova.com
Gantofiban
CAS No. 183547-57-1
Gantofiban( —— )
Catalog No. M36175 CAS No. 183547-57-1
Gantofiban is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist used in the treatment of cardiovascular disease and may be used to study thrombosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 290 | Get Quote |
|
| 5MG | 456 | Get Quote |
|
| 10MG | 653 | Get Quote |
|
| 25MG | 994 | Get Quote |
|
| 50MG | 1362 | Get Quote |
|
| 100MG | 1791 | Get Quote |
|
| 500MG | 3528 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGantofiban
-
NoteResearch use only, not for human use.
-
Brief DescriptionGantofiban is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist used in the treatment of cardiovascular disease and may be used to study thrombosis.
-
DescriptionGantofiban is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist used in the treatment of cardiovascular disease and may be used to study thrombosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number183547-57-1
-
Formula Weight447.48
-
Molecular FormulaC21H29N5O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1N(C[C@@H](CN2CCN(CC(OCC)=O)CC2)O1)C3=CC=C(C(NC(OC)=O)=N)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
LLP2A
LLP2A is a high-affinity, selective peptidomimetic ligand of α4β1 integrin with IC50 of 2 pM.
-
LXW7
LXW7 is an octamer disulfide cyclic peptide and αvβ3 integrin ligand, acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand. LXW7 is a disulfide cyclic octa-peptide (cGRGDdvc) containing unnatural amino acids flanking both sides of the main functional motif.
-
Echistatin, α1 isofo...
Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) receptors (IC50 = 30 nM) in vitro.
